en · de · es · fr · pt
peptide-index.peptides7501.com › Guide › Background And Mechanism Of Sr9009 — Beginner to Advanced

Background And Mechanism Of Sr9009 — Beginner to Advanced

By Editorial Desk · published 2025-10-30 · last reviewed 2025-12-16 · Guide

SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Analytical Detection and Storage

Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.

Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Handling, Analysis, and Regulation

Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.

Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.

Related pages on this site

Further detail

== Conservation status == Rattlesnakes tend to avoid developed areas, preferring undisturbed, natural habitats. Rapid habitat destruction by humans, mass killings during events such as rattlesnake round-ups, and deliberate extermination campaigns all pose threats to rattlesnake populations in many areas. Several species, such as the timber rattlesnake, massasauga, and canebrake rattlesnake, are listed as threatened or endangered in many U.S. states. Many rattlesnakes die from being run over by cars. In more heavily populated and trafficked areas, reports have been increasing of rattlesnakes that do not rattle. This phenomenon is falsely attributed to selective pressure by humans, who often kill the snakes when they are discovered. However, snake experts have dismissed this theory, stating that snakes simply do not rattle as often as laymen expect them to, and that snakes that live near populated areas simply get used to people passing by, only rattling when a person lingers too long or gets too close.

Liu Wenhui (simplified Chinese: 刘文辉; traditional Chinese: 劉文輝; pinyin: Liú Wénhuī; Wade–Giles: Liu Wen-hui; 10 January 1895 – 24 June 1976) was a Chinese general and warlord of Sichuan and Xikang provinces (Sichuan clique). At the beginning of his career, he was aligned with the Kuomintang (KMT), commanding the Sichuan-Xikang Defence Force from 1927 to 1929. In 1929, he became Sichuan governor before being ousted by a coalition of warlords in 1933; from there, he controlled the western part of Sichuan province, then known as Xikang, ruling the area as a personal fiefdom. He maintained his autonomy from the Nationalist government and pursued development programs in the province, which he funded through the trade of opium and by maintaining cordial relations with Chiang Kai-shek during the Second Sino-Japanese War. In 1949 he defected to the Communist forces of Mao Zedong, and went on to hold high office in the new People's Republic of China, serving as Minister of Forestry (1959–1967), member of the National People's Congress, member of the National Committee of the Chinese People's Political Consultative Conference, and member of the Central Committee of the Revolutionary Committee of the Chinese Kuomintang.

=== Interest in William James === During his first trip to the United States with Freud, Jung was introduced to the elder philosopher and psychologist William James, known as the "Father of American psychology," whose ideas Jung would incorporate into his own work. Jung connected with James around their mutual interests in mysticism, spiritualism and psychical phenomena. James wrote to a friend after the conference stating Jung "left a favorable impression," while "his views of Freud were mixed." James died about eleven months later. The ideas of both Jung and James, on topics including hopelessness, self-surrender, and spiritual experiences, were influential in the development and founding of the international altruistic, spiritual movement Alcoholics Anonymous on 10 June 1935, in Akron, Ohio, a quarter of a century after James' death and in Jung's sixtieth year.

One of the journal studies found that a childhood vaccination strategy will be much cheaper than reacting to future epidemics with disruptive and costly case management and mass vaccination campaigns.

Sources: en.wikipedia.org

Supporting material

== Symbol encoding in character sets == The official symbol for the SI prefix micro is a Greek lowercase mu (μ). For reasons stemming from its design, Unicode has two different character codes for the letter, with slightly different appearance in some computer fonts, although most fonts use the same glyph. U+03BC μ GREEK SMALL LETTER MU is in the Greek range. According to The Unicode Consortium, the Greek letter character is preferred, but implementations must recognize the micro sign as well, for compatibility with legacy character sets. This distinction also occurs in some legacy code pages, notably Windows-1253. In circumstances in which only the Latin alphabet is available, ISO 2955 (since 1974, withdrawn 2001), DIN 66030 (since 1980) and BS 6430 (since 1983) allow the prefix μ to be substituted by the letter ⟨u⟩ (U+0075 u LATIN SMALL LETTER U) as, for example, in um for μm, or uF for μF . Similarly, capacitor values according to the RKM code defined in IEC 60062 (since 1952) can be written as 4u7 (or 4U7) instead of 4μ7 if the Greek letter μ is not available. The CJK Compatibility block contains square forms of some Japanese katakana measure and currency units. U+3343 ㍃ SQUARE MAIKURO corresponds to マイクロ maikuro.

=== Other applications === One of the most desirable uses for protein design is for biosensors, proteins that will sense the presence of specific compounds. Some attempts in the design of biosensors include sensors for unnatural molecules including TNT. More recently, Kuhlman and coworkers designed a biosensor of the PAK1. In a sense, protein design is a subset of battery design.

=== Pharmacodynamics === Methocinnamox is an opioid receptor antagonist, it works at the μ-opioid receptor. By acting as an antagonist, it binds to the receptor but does not activate it, thus blocking the action of agonists such as heroin and fentanyl. It is a pseudo-irreversible non-competitive antagonist of the μ-opioid receptor and a competitive antagonist of the κ- and δ-opioid receptors. Methocinnamox has affinity values for the opioid receptors of 0.6 nM for the μ-opioid receptor, 2.2 nM for the δ-opioid receptor, and 4.9 nM for the κ-opioid receptor. Hence, it has about 3.7-fold preferential affinity for the μ-opioid receptor over the δ-opioid receptor and about 8.2-fold higher affinity for the μ-opioid receptor over the κ-opioid receptor. The antagonism of the μ-opioid receptor by methocinnamox is not irreversible as the drug does not form a covalent bond with the receptor. This is in contrast to prototypical μ-opioid receptor alkylating agents like β-funaltrexamine and β-chlornaltrexamine. However, in spite of its lack of covalent binding to the μ-opioid receptor, methocinnamox appears to not dissociate from the μ-opioid receptor or dissociates from it extremely slowly. Hence, methocinnamox has been described as a pseudo-irreversible antagonist of the μ-opioid receptor or as a "functionally irreversible" antagonist. The mechanism underlying the pseudo-irreversible antagonism of methocinnamox hasn't been fully elucidated.

Sources: en.wikipedia.org

Notes from published material

It was deemed significant that the bizarre cases of hypoglycaemia appeared to follow Norris when he transferred to the new hospital —‍especially since he was the only staff member who had been transferred. He was the only staff member who worked on both the wards in the two hospitals where all the hypoglycaemic incidents were occurring. A colleague later stated that Norris had shown no desire to revive Crookes after she fell into a coma. Another colleague also later testified that Norris had watched in "detached amusement" after one of the victims had fallen into a coma. She said that "everything he did that night had to be prompted". Significantly, it was discovered by a member of staff that they had suddenly run out of insulin after Crooke's hypoglycaemic attack. It is believed that by the time Hall was killed, Norris had become confident he could carry on killing without being caught since no blood tests for insulin had been done. He would not have expected, therefore, a blood sample to be taken from Hall and sent to a specialist laboratory as it was, which finally led to him being caught, expecting the death would be considered due to natural causes. None of the patients had been prescribed insulin by any doctors or medical staff members in the hospital. All the victims were considered somewhat "difficult" patients, which likely irritated Norris with his dislike for elderly patients. One of the women had been throwing her bedclothes off just before he killed her.

Experiments done in dwarf chameleons testing these hypotheses showed that chameleon taxa with greater capacity for color change had more visually conspicuous social signals but did not come from more visually diverse habitats, suggesting that color change ability likely evolved to facilitate social signaling, while camouflage is a useful byproduct. Because camouflage is used for multiple adaptive purposes in cephalopods, color change could have evolved for one use and the other developed later, or it evolved to regulate trade offs within both.

=== General and cited references === Chinn, George M., ed. (1987). The Machine Gun: History, Evolution, and Development of Manual, Automatic, and Airborne Repeating Weapons (PDF). Vol. V. Ann Arbor, Michigan: Edward Brothers Publishing Co. Retrieved 28 April 2019.

=== Portal hypertension === The portal vein also known as the hepatic portal vein carries blood drained from most of the gastrointestinal tract to the liver. Portal hypertension is mainly caused by cirrhosis of the liver. Other causes can include an obstructing clot in a hepatic vein (Budd Chiari syndrome) or compression from tumors or tuberculosis lesions. When the pressure increases in the portal vein, a collateral circulation develops, causing visible veins such as esophageal varices.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

How is SR9009 measured?

Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.

Network